Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Radiopharm Theranostics Limited ( (AU:RAD) ) is now available.
Radiopharm Theranostics Limited has released its annual report for the fiscal year ended June 30, 2025, as required by the United States Securities and Exchange Commission. The company’s listing on the Nasdaq Stock Market signifies its commitment to expanding its market presence and enhancing its visibility among investors. This announcement may impact the company’s operations by potentially increasing its access to capital and improving its industry positioning.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited operates in the biotechnology industry, focusing on the development of radiopharmaceutical products for diagnostic and therapeutic purposes. The company is listed on the Nasdaq Stock Market under the trading symbol RADX and is incorporated in Australia.
Average Trading Volume: 3,509,371
Technical Sentiment Signal: Hold
Current Market Cap: A$73.31M
See more insights into RAD stock on TipRanks’ Stock Analysis page.